spacer
home > ict > autumn 2009 > electronic patient identification
PUBLICATIONS
International Clinical Trials

Electronic Patient Identification

 

THE NEED FOR CHANGE

Recruiting patients today for clinical trials is a high-touch, highcost business with many players and no economy of scale. Clinical trials are the gateway to revenue for the pharmaceutical, medical device and biotech industries, as pharmaceutical companies anticipate losing 33 per cent of their revenue in the next few years due to generics and drug patent expiry. Spending on R&D has grown by 37 per cent, from $51 billion in 2005 to $70 billion in 2009, while the number of new drug applications has dropped. It is clear that the development process must work faster and ensure that no product fails for lack of test subjects.

On average, difficulties in patient enrolment delay 81 per cent of all clinical trials from one to six months, costing pharmaceutical companies as much as $8 million each day (1). In addition, patient recruiting in 2009 will cost approximately $16 billion of the $70 billion to be spent on R&D, and require an average of 26 per cent of the time required for each trial. Recruiting reimbursement paid by the pharma industry to investigators ranges from $1,500 to over $10,000 per patient for trials requiring patients who are hard to locate. Existing methods of finding patient candidates include consumer market research, advertising and physician referrals – methods that are not meeting the needs for drug and medical device development and innovation.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
CEO and co-founder of KDH Systems, David Haddick has 25 years’ experience designing products in association with and for physicians, primarily in the field of medical imaging. While Vice President of Engineering for Dunn Instruments he produced a number of patented products, subsequently licensed by Fuji Medical, Japan. He then founded his own successful consulting practice which, for over 10 years, distributed a variety of US and European imaging products in Japan, and also developed and sold his own system of medical imaging cameras. Prior to founding KDH, David was Product Manager for CardioMatch diagnostic software for cardiology, and was instrumental in initiating and directing clinical trials at leading medical institutions worldwide. He holds a BSEE degree from the University of California, Berkeley.
spacer
David Haddick
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

DuPont Achieves Non-GMO Certification for SeaGel®, Reinforces Commitment to Sustainable, Quality Ingredients


More info >>

White Papers

The Promise and Challenge of Adaptive Design in Oncology Trials

Medpace

Clinical oncology trials are more complex and time consuming than those in any other therapeutic area and failure rates are frustratingly high. Given the urgent need for new oncologic therapies, sponsors are eager to find more effective ways to conduct clinical research. Incorporating adaptive design methodologies into clinical trials can reduce costs and enhance efficiency while maintaining trial integrity. They can also reduce the number of patients on placebo and sub-therapeutic doses. In light of this promise, regulatory bodies have created guidelines supportive of adaptive design.
More info >>

 
Industry Events

Evolution Summit

20-22 July 2020, The Ritz Carlton, Fort Lauderdale, FL

The 22nd Evolution Summit is the premium forum bringing leading drug development executives and solution providers together. As an invitation-only event, taking place behind closed doors, the Summit offers an intimate environment for a focused discussion of key new drivers shaping drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement